<DOC>
	<DOC>NCT02725476</DOC>
	<brief_summary>The purpose of this Phase 2 study is to investigate the effect of XmAb5871 on IgG4-Related Disease (RD) activity</brief_summary>
	<brief_title>Study to Evaluate the Effect of XmAb®5871 on Disease Activity in Patients With IgG4-Related Disease (RD)</brief_title>
	<detailed_description />
	<criteria>Active IgG4RD Compatible pattern of organ involvement consistent with IgG4RD that cannot be attributed to other causes Histopathologicallyproven diagnosis of IgG4RD Peripheral blood plasmablast count &gt;900 cells/mL and/or elevated IgG4RD levels during screening Able and willing to complete the entire study according to the study schedule Able and willing to provide written informed consent History or evidence of a clinically unstable/uncontrolled disorder, condition or disease other than IgG4RD that, in the opinion of the Investigator would pose a risk to the patient safety or interfere with the study evaluation, procedures or completion Malignancy within 5 years (except successfully treated in situ cervical cancer, resected squamous cell or basal cell carcinoma of the skin, or prostate cancer with no recurrence ≥3 years following prostatectomy) Presence of recurrent or chronic infections, defined as ≥3 infections requiring antimicrobials over the past 6 months prior to screening Active infection requiring hospitalization or treatment with parenteral antimicrobials within the 60 days prior to randomization or oral antimicrobials within the 21 days prior to enrollment Patient is taking &gt;40 mg of prednisone QD Prior use of rituximab (or other B cell depleting agents) within 6 months of enrollment. Prior use of any B cell depleting agent greater than 6 months from enrollment is allowed if the CD19+ B cell count is within the normal reference range during screening Use of any investigational agent within 5 halflives of the agent (or 6 months if the halflife is unknown) prior to enrollment Immunosuppressive agent use within the three months prior to enrollment Has received live vaccines within 2 months of enrollment Patient is pregnant or breast feeding, or planning to become pregnant while enrolled in the study, up to endofstudy visit Unable or unwilling to partake in the followup assessments or required protocol procedures</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>March 2016</verification_date>
</DOC>